leisure time -WSS

leisure time

author：comprehensive 2025-10-02 10:45:24 - browse：99

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Reporting on presidential health from Reagan to Trump and Biden

knowledge

WSS

Study suggests Covid rebound is far more common with Paxlovid than without

In 'major milestone,' FDA approves first cell therapy for solid tumors

Medicare’s new pay boost for primary care is angering specialists

First transplant of an entire human eye performed

Cancer diagnosis changes perspective doctor, former hospital CEO

Obamacare plans could cover weight loss drugs

knowledge

leisure time

entertainment

Medicare details structure of new drug price negotiation program

Opioid cravings were reduced by anti

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

23andMe had bad news about my health. I wish a person had delivered it

Carbon Health diabetes program, a test of data

Activists slam private health insurers over coverage restrictions

Surprise medical billing ban raises prices elsewhere

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

hotspot

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Ventyx halts psoriasis drug development after lackluster trial results

Researchers tackle phage therapy hurdles for wider adoption

New study raises questions about niacin and heart health

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

MD Anderson's Padmanee Sharma responds to research credit suit

knowledge

entertainment

knowledge

knowledge